Growth Hormone and Obesity
- Resource Type
- Authors
- Steen B. Pedersen; Morten Hogild; Niels Møller; Niels Jessen; Bjørn Richelsen; Ann Mosegaard Bak; Astrid Johannesson Hjelholt; Amanda Bæk; Mai Christiansen Arlien-Søborg; Jens Otto Lunde Jørgensen
- Source
- Hjelholt, A, Høgild, M, Bak, A M, Arlien-Søborg, M C, Bæk, A, Jessen, N, Richelsen, B, Pedersen, S B, Møller, N & Lunde Jørgensen, J O 2020, ' Growth Hormone and Obesity ', Endocrinology and Metabolism Clinics of North America, vol. 49, no. 2, pp. 239-250 . https://doi.org/10.1016/j.ecl.2020.02.009
- Subject
- medicine.medical_specialty
Anabolism
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
030209 endocrinology & metabolism
Growth hormone
Fat mass
03 medical and health sciences
0302 clinical medicine
Endocrinology
Internal medicine
medicine
Humans
Obesity
Insulin-Like Growth Factor I
Human Growth Hormone
business.industry
Insulin
Insulin-like growth factor I
Fasting
medicine.disease
Growth hormone secretion
Adipose Tissue
030220 oncology & carcinogenesis
Lean body mass
Gh treatment
business
- Language
- English
Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.